We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.54%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$855M
AUM Growth
+$208M
Cap. Flow
+$133M
Cap. Flow %
15.53%
Top 10 Hldgs %
33.51%
Holding
104
New
21
Increased
54
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$28.3M
2
STJ
St Jude Medical
STJ
+$21.6M
3
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$9.49M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$9.39M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$9.37M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$13.2M
2
GILD icon
Gilead Sciences
GILD
+$11.2M
3
PCRX icon
Pacira BioSciences
PCRX
+$9.89M
4
ATHN
Athenahealth, Inc.
ATHN
+$8.92M
5
CAH icon
Cardinal Health
CAH
+$6.91M

Sector Composition

Rank Sector Weight
1 Healthcare 73.14%
2 Financials 1.36%
3 Technology 0.94%
4 Industrials 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDT icon
1
Medtronic
MDT
$112B
$39.7M 4.65%
550,000
+22,500
+4% +$1.56M
ABBV icon
2
AbbVie
ABBV
$465B
$38M 4.44%
580,000
+55,000
+10% +$3.47M
COV
3
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$30.2M 3.53%
+295,000
New +$28.3M
HCA icon
4
HCA Healthcare
HCA
$88.4B
$29.9M 3.5%
408,000
+87,750
+27% +$6.17M
MCK icon
5
McKesson
MCK
$104B
$29M 3.39%
139,750
+11,250
+9% +$2.29M
AMGN icon
6
Amgen
AMGN
$209B
$25.6M 3%
161,000
+16,000
+11% +$2.49M
MRK icon
7
Merck
MRK
$322B
$25.6M 2.99%
471,600
-26,200
-5% -$1.46M
GILD icon
8
Gilead Sciences
GILD
$165B
$24M 2.81%
255,000
-108,000
-30% -$11.2M
AGN
9
DELISTED
Allergan plc
AGN
$22.7M 2.65%
88,000
+250
+0.3% +$62.5K
STJ
10
DELISTED
St Jude Medical
STJ
$21.8M 2.55%
+335,000
New +$21.6M
CELG
11
DELISTED
Celgene Corp
CELG
$21.6M 2.53%
193,000
+27,000
+16% +$2.85M
ACHC icon
12
Acadia Healthcare
ACHC
$2.55B
$20.2M 2.36%
329,750
+126,750
+62% +$7.38M
AVNR
13
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$18.6M 2.18%
1,100,000
– –
THOR
14
DELISTED
THORATEC CORPORATION
THOR
$17.3M 2.03%
533,500
+12,500
+2% +$364K
ALXN
15
DELISTED
Alexion Pharmaceuticals
ALXN
$17.1M 2%
92,500
+2,750
+3% +$510K
BIIB icon
16
Biogen
BIIB
$30.9B
$15.4M 1.81%
45,500
-15,850
-26% -$5.13M
TMH
17
DELISTED
Team Health Holdings Inc
TMH
$15.3M 1.79%
266,500
+115,750
+77% +$6.67M
CVS icon
18
CVS Health
CVS
$135B
$14.4M 1.69%
150,000
+20,000
+15% +$1.76M
HUM icon
19
Humana
HUM
$43.9B
$13.8M 1.62%
96,250
+16,750
+21% +$2.29M
AET
20
DELISTED
Aetna Inc
AET
$11.6M 1.36%
131,000
+25,000
+24% +$2.1M
AVDL
21
DELISTED
Avadel Pharmaceuticals
AVDL
$11.6M 1.35%
675,000
-60,000
-8% -$857K
EVHC
22
DELISTED
Envision Healthcare Holdings Inc
EVHC
$10.9M 1.28%
105,210
+9,853
+10% +$1.01M
PCYC
23
DELISTED
PHARMACYCLICS INC
PCYC
$10.8M 1.27%
88,500
+3,250
+4% +$415K
HRC
24
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$10.3M 1.2%
225,000
+12,000
+6% +$532K
OREX
25
DELISTED
Orexigen Therapeutics, Inc.
OREX
$10.2M 1.19%
168,500
+43,500
+35% +$2.18M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, Rock Springs Capital Management held 104 positions worth $855M, up 32% from $646M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management deployed $133M of net new capital in Q4 2014, opening 21 new positions and adding to 54 existing holdings. Its largest new stake was COVIDIEN PLC COM SHS NEW (IRELAND): 295,000 shares worth $30.2M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 79% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Gilead Sciences, an estimated $11.2M trimmed.

  • Rock Springs Capital Management's largest Q4 2014 buy was COVIDIEN PLC COM SHS NEW (IRELAND): 295,000 shares worth $30.2M.
  • Rock Springs Capital Management added most to Acadia Healthcare in Q4 2014, an estimated $7.38M increase.
  • Rock Springs Capital Management's biggest Q4 2014 reduction was Gilead Sciences, cutting an estimated $11.2M.
  • Rock Springs Capital Management fully exited Thermo Fisher Scientific in Q4 2014, selling an estimated $13.2M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $855M portfolio in Q4 2014.
  • Rock Springs Capital Management opened 21 new positions and closed 11 in Q4 2014.
  • Rock Springs Capital Management's portfolio value rose 32% quarter-over-quarter to $855M.

Based on Rock Springs Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.